Experimental trials were performed to evaluate the efficacy of oxytetracycline in controlling Streptococcus iniae infection in blue tilapia Tilapia aurea. Minimum-inhibitory-concentration studies of oxytetracycline against multiple S. iniae isolates indicated a general sensitivity at concentrations of 0.25–0.50 μg/mL. The dose levels tested were 25, 50, 75, and 100 mg active ingredient per kilogram of fish body weight per day. Administration of medicated feed started within 4–5 h after infection by waterborne exposure to S. iniae (after skin scraping) and continued for 14 consecutive days, followed by a posttreatment period of 21 d. The 50-mg treatment significantly increased the survival of infected fish from 7% in the nonmedicated group to 45%. The 75- and 100-mg treatments had survival rates (85% and 98%, respectively) that were significantly higher than that of the 50-mg treatment. There was no significant difference between the 75- and 100-mg treatments and the uninfected, nonmedicated treatment (100% survival). Survivors from the 100-mg treatment were not found to be carriers of the infection (negative bacterial isolation), whereas the bacterium was recovered from 10% of the survivors from the 75-mg treatment.
No takes yet. Share an insight, caveat, or question.
Darwish et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: